Amplity, a leading global contract medical and commercial organization, announced today it has appointed Chris Baker to the position of Chief Executive Officer (CEO), effective immediately. Michael A. Griffith, Amplity founder and long-standing CEO, will transition to the role of Chairman of the Board of Directors as part of a deliberate succession plan. In this capacity, he will continue to support Baker and the leadership team, but with a primary focus on building the visibility and awareness of Amplity in the biopharmaceutical market.
“More and more, we are seeing a convergence between medical engagement and commercial engagement,” says Griffith. “Chris brings significant leadership experience in large pharma commercial operations, contract research, and data to this role. Her background and track record of growth are unique and make her a great fit for Amplity. I am delighted to introduce Chris as our new CEO and look forward to supporting her as she works to accelerate our success.”
“Amplity is a high-quality medical and sales engine positioned squarely where the market is heading: the intersection where clinical, medical affairs, and commercial biopharma teams are working tirelessly to accelerate and maximize launch effectiveness and patient access to life-saving oncology, rare disease, and specialty medicines,” says Baker, who will also serve on Amplity’s Board of Directors.
“We have the very best medical liaison and specialty sales talent to help drive physician and patient adoption,” she continues. “By maintaining our focus on the highest quality personnel, and leveraging the right data to drive exceptional delivery, we will continue to expand our role as a trusted partner of choice to biopharma customers. I look forward to working with Mike, the Board, and our talented leadership team to achieve this vision.”
According to Griffith, this transition takes place at an exciting point in Amplity’s existence.
“Amplity currently has more than 90 medical and commercial programs under management in 41 countries, and started 2024 with 20% greater program backlog year over year,” he says. “We have also strengthened our internal teams with the introduction of dynamic, new leaders. I look forward to partnering with Chris and the team to build on this success, while challenging our model to incorporate deeper, proprietary data-led solutions.”
Baker joins Amplity from ICON plc where she was most recently the President of the Symphony Health division, a leading provider of high-value data, tokenization, and technology solutions for healthcare companies. Previously, Baker was the Executive Vice President and Global Head of Parexel’s Clinical FSP outsourcing business. She also served as a Vice President at Pfizer where she held Sales and Marketing leadership positions including completing an Expat tour in South Africa. Baker earned her MBA from The University of Chicago’s Booth School of Business and was a D1 volleyball player at Penn State University where she earned her bachelor’s degree.
Expert-led teams that deliver.
Pharma at its best: Quicker. Better. Nicer.
Your full-service go-to partners delivering both flexible and specialized medical and commercial services. No matter where you are in the lifecycle of your drug, we scale with ease.
Our people-driven tech-enabled DNA fuels everything we do.
To connect with Amplity’s Marketing and PR team, please email [email protected].
